Additional file 1: Figure S1. of Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer

Correlation of PAR-1 expression and specific markers for endothelial cells, macrophages and myofibroblasts. Consecutive lung cancer slides stained for PAR-1 (left panels), CD31 (endothelial marker), CD68 (macrophage marker) and aSMA (myofibroblast marker). Please note that due to the use of consecutive slides, the structure of the tissue in the PAR-1 stained slide is somewhat different from the CD31, CD68 and aSMA stained slides. Pictures were taken with 100x magnification. (TIF 7026 kb

Overall gene-expression profile of triple-negative tumors associated with disease outcome

<p><b>Copyright information:</b></p><p>Taken from "Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas"</p><p>http://breast-cancer-research.com/content/9/5/R65</p><p>Breast cancer research : BCR 2007;9(5):R65-R65.</p><p>Published online 2 Oct 2007</p><p>PMCID:PMC2242660.</p><p></p> (a) Hierarchical cluster analysis of the overall gene-expression profile of 71 triple-negative tumors with identifiable gene clusters indicated on the right hand side. (b) Metastasis-free survival of 71 patients with triple-negative breast carcinomas, comparing the left branch with the right branch of the overall gene-expression hierarchical cluster analysis

Association of pathological and immunohistochemical characteristics with the overall gene-expression profile of triple-negative tumors

<p><b>Copyright information:</b></p><p>Taken from "Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas"</p><p>http://breast-cancer-research.com/content/9/5/R65</p><p>Breast cancer research : BCR 2007;9(5):R65-R65.</p><p>Published online 2 Oct 2007</p><p>PMCID:PMC2242660.</p><p></p> Distribution of tumor type and immunohistochemical staining for KRT5/6, epidermal growth factor receptor (EGFR) and KIT in the dendogram of the 97 triple-negative tumors after hierarchical clustering of these samples based on the expression of 7,770 genes

Additional file 2: Figure S2. of Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

Chronic treatment with gefitinib and PWT-458, alone or in combination, does not cause eight loss in mice. Mice bearing MDA-MB-468 xenograft tumors were treated with PWT-458 (100 mg/kg five imes/week), gefitinib (150 mg/kg five times/week), combination of both drugs, or vehicle control. The mouse body weight was measured in control and treated groups using a weighing scale. The results represent the mean body weight Âą S.E.M. (n = 5 mice per group). (PDF 880 kb

La Vigie marocaine

12 mai 19371937/05/12 (A28,N9288)-1937/05/12

Additional file 7: of HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Ten-fold internal cross-validations to identify an optimal DNAme signature. Upper panel shows the total misclassification error (y-axis) as a function of the shrinkage threshold (x-axis) used. Lower panel shows the misclassification error for each phenotype (1 = low HOTAIR expression, 2 = high HOTAIR expression) as a function of the same shrinkage threshold. The optimal minimal classifier was found at a threshold of approximately 1.47, corresponding to a 67-CpG signature at an estimated false discovery rate (FDR) of approximately 0.17 (not shown). The FDR was estimated using a permutation scheme as implemented in the pamr R-package, and the relatively low FDR (only about 17 % of the 67 CpGs are expected to be false positives) demonstrates the presence of a genuine DNAme signal associated with HOTAIR expression. (PDF 13 kb